Kenya at a glance
- Population
- 57.5 million 2025
- Life expectancy at birth
- 63.8 years, 2024
- People aged 65 and over
- 3.0 % of people, 2025
- Health spending per person
- 85 US$ per person, 2023
- Doctors
- 0.29 per 1,000 people, 2023
Updated
Reviewed by Chandani Patel
Kenya Cancer Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$166.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $85.9 Mn | — | — |
| 2025 (base) | $96.0 Mn | +$10.1 Mn | — |
| 2026 (forecast) | $107.3 Mn | +$11.3 Mn | +11.8% |
| 2027 (forecast) | $120.0 Mn | +$12.7 Mn | +25% |
| 2028 (forecast) | $134.1 Mn | +$14.2 Mn | +39.7% |
| 2029 (forecast) | $150.0 Mn | +$15.8 Mn | +56.2% |
| 2030 (forecast) | $167.7 Mn | +$17.7 Mn | +74.7% |
| 2031 (forecast) | $187.5 Mn | +$19.8 Mn | +95.3% |
| 2032 (forecast) | $209.6 Mn | +$22.1 Mn | +118.3% |
| 2033 (forecast) | $234.3 Mn | +$24.7 Mn | +144.1% |
| 2034 (forecast) | $262.0 Mn | +$27.6 Mn | +172.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $96.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $262.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, indication and end user (see all) |
| Key players | Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Regeneron Pharmaceuticals (see all) |
| Regulator in Kenya | PPBSource: Pharmacy and Poisons Board. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Cancer immunotherapy helps the immune system fight cancer, using checkpoint inhibitors, cell therapies, vaccines and other immune drugs.
Key segments of the cancer Immunotherapy market include type (Checkpoint Inhibitors, Cell Therapies and Cancer Vaccines) and indication (Lung Cancer, Melanoma and Blood Cancers).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Immunotherapy market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Immunotherapy market, especially in low- and middle-income countries.
The cancer Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The Pharmacy and Poisons Board (PPB) registers medicines before sale.[1] The Social Health Authority (SHA) replaced the National Health Insurance Fund (NHIF) in October 2024.[2]
[1] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[2] Social Health Authority. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Kenya.
What doctors and scientists are doing in Cancer Immunotherapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
Kenya · 3 shared keywords
Kenya · 3 shared keywords
Kenya · 2 shared keywords
Kenya · 1 shared keyword
Kenya · 1 shared keyword
Kenya · 1 shared keyword
Public Health · Kenya
Digital Health · Kenya
Healthcare Services · Kenya
Healthcare Services · Kenya
Healthcare Services · Kenya
Public Health · Kenya